Provided by Tiger Trade Technology Pte. Ltd.

Alpha Tau Medical

14.43
-0.0100-0.07%
Post-market: 14.680.2500+1.73%16:29 EDT
Volume:405.28K
Turnover:5.78M
Market Cap:1.33B
PE:-13.72
High:14.62
Open:14.49
Low:14.01
Close:14.44
52wk High:15.17
52wk Low:3.43
Shares:92.33M
Float Shares:63.79M
Volume Ratio:0.72
T/O Rate:0.64%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.0517
EPS(LYR):-0.5300
ROE:-141.68%
ROA:-25.71%
PB:30.24
PE(LYR):-27.23

Loading ...

CORRECTION: Alpha Tau Medical Q1 EPS $(0.26) Misses $(0.12) Estimate

Benzinga Earnings
·
May 19

Alpha Tau Q1 FY26 net loss more than doubles to $22.9 million

Reuters
·
May 19

Press Release: Alpha Tau Announces First Quarter 2026 Financial Results and Provides Corporate Update

Dow Jones
·
May 19

Alpha Tau Medical Ltd options imply 16.0% move in share price post-earnings

TIPRANKS
·
May 19

Alpha Tau CFO Levy joins H.C. Wainwright BioConnect investor conference fireside chat

Reuters
·
May 18

Alpha Tau to Participate in May Investor Conferences

GlobeNewswire
·
May 18

Alpha Tau price target raised to $14 from $12 at Ladenburg

TIPRANKS
·
May 12

Analysts Have Conflicting Sentiments on These Healthcare Companies: BioNTech SE (BNTX), Personalis (PSNL) and Alpha Tau Medical Ltd (DRTS)

TIPRANKS
·
May 12

Alpha Tau Medical Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
May 12

Alpha Tau Medical Ltd. : H.c. Wainwright Raises Target Price to $15 From $12

THOMSON REUTERS
·
May 12

Alpha Tau Medical Shares Interim U.S. Glioblastoma Trial Data for Alpha DaRT

TIPRANKS
·
May 11

Alpha Tau Says Complete Response in 2 Brain Cancer Patients Observed in Interim Trial of Radiation Treatment

MT Newswires Live
·
May 11

Alpha Tau Alpha DaRT glioblastoma trial shows 67% complete response in interim data

Reuters
·
May 11

Alpha Tau Announces Groundbreaking Interim Results From Its U.S. Alpha Dart® Recurrent Glioblastoma Trial, With 100% Local Disease Control, 67% Complete Response Rate, and Favorable Safety Profile Observed - Conference Call Scheduled for 8:30Am Et

THOMSON REUTERS
·
May 11

Alpha Tau Medical Ltd - One Associated Grade 3 Serious Adverse Event Was Observed, Since Resolved

THOMSON REUTERS
·
May 11

Alpha Tau Medical Ltd - No Unanticipated Serious Adverse Events Observed as of May 3, 2026

THOMSON REUTERS
·
May 11

Alpha Tau completes enrollment in pivotal ReSTART trial for recurrent skin cancer

Reuters
·
May 08

Alpha Tau Completes Patient Enrollment in Its U.S. Pivotal Skin Cancer Study, Advancing Towards Goal of FDA Approval of Alpha Dart® to Treat Recurrent Cutaneous Squamous Cell Carcinoma

THOMSON REUTERS
·
May 08

Alpha Tau treats first patient with Alpha DaRT in Italy

TIPRANKS
·
May 08

Alpha Tau Medical Ltd: Successfully Treats First Pancreatic Cancer Patient in Italy With Alpha Dart

THOMSON REUTERS
·
May 07